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Screening for Lung Cancer with Low-Dose Computed
Tomography
A Systematic Review and Meta-Analysis of the Baseline Findings of
Randomized Controlled Trials
Muralikrishna Gopal, MD,* Shaad E. Abdullah, MD,† James J. Grady, DrPH,‡§
and James S. Goodwin, MD¶
Objectives: Lung cancer is the leading cause of death among all
cancers. An estimated 29% of the global population older than 15
years currently smokes tobacco. The presence of a high risk
population, relatively asymptomatic nature of the disease in the
early phase, and relatively good prognosis when discovered early
makes screening for lung cancer an attractive proposition. We
performed a systematic review and a meta-analysis of the base-
line results of randomized controlled trials so far published,
which included more than 14,000 patients. Analysis was used to
determine whether data was for or against the screening of lung
cancers using low-dose computed tomography (LDCT).
Design: Random effect meta regression model of meta-analysis and
systematic review.
Methods: We performed a systematic review and a meta-analysis
of the current literature to determine whether screening for lung
cancer in a high-risk population with computed tomography
improves outcomes. A search strategy using Medline was em-
ployed, studies selected based on preset criteria and application
of exclusion criteria, and data collected and analyzed for statis-
tical significance.
Results: Screening for lung cancer using LDCT resulted in a
significantly higher number of stage I lung cancers (odds ratio 3.9,
95% confidence interval [CI] 2.0–7.4), higher number of total
non-small cell lung cancers (odds ratio 5.5, 95% CI 3.1–9.6), and
higher total lung cancers (odds ratio 4.1, 95% CI 2.4–7.1). Screen-
ing using LDCT also resulted in increased detection of false-positive
nodules (odds ratio 3.1, 95% CI 2.6–3.7) and more unnecessary
thoracotomies for benign lesions (event rate 3.7 per 1000, 95% CI
3.5–3.8). For every 1000 individuals screened with LDCT for lung
cancer, 9 stage I non-small cell lung cancer and 235 false-positive
nodules were detected, and 4 thoracotomies for benign lesions were
performed.
Conclusions: The baseline data from six randomized controlled
trials offer no compelling data in favor or against the use of LDCT
screening for lung cancer. We await the final results of these
randomized controlled trials to improve our understanding of the
effectiveness of LDCT in the screening for lung cancer and its effect
on mortality.
Key Words: Lung cancer, Screening, Computed tomography,
LDCT.
(J Thorac Oncol. 2010;5: 1233–1239)
Lung cancer is the leading cause of death among allcancers and continues to have a high mortality, despite
advances in treatment.1,2 Increased incidence in smokers is
well known, and prior studies have shown that tumors that
are detected at an earlier stage show better 5-year survival
rates.3,4 An estimated 29% of the global population older
than 15 years currently smokes tobacco.5 A number of
trials of screening for early lung cancer using chest radi-
ography and sputum cytology have not shown a significant
benefit from screening.6–14 Most early studies using low-
dose computed tomography (LDCT) have been prospective
cohort studies, the implication of these studies being
limited by lead time bias.15 Screening for lung cancer has
been a topic of debate, and both feasibility and benefit
from such screening have been questioned.16–19 Although
summaries of baseline findings from randomized con-
trolled trials (RCTs) involving LDCT have been published,
a meta-analysis has not been performed. Two systematic
reviews have been published on LDCT in lung cancer
screening,20,21 these included single-arm prospective co-
Departments of *Pulmonary/Critical Care, and †Hematology/Oncology, Al-
bert Einstein College of Medicine/Montefiore Medical Center, Bronx,
New York; ‡Department of Preventive Medicine and Community Health,
Division of Epidemiology and Biostatistics, §Office of Biostatistics, and
General Clinical Research Center; and ¶Sealy Center of Aging, Univer-
sity of Texas Medical Branch, Galveston, Texas.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Muralikrishna Gopal, MD, Department of
Pulmonary/Critical Care, Albert Einstein College of Medicine/Monte-
fiore Medical Center, 111 E210th Street, Bronx, NY 10467. E-mail:
murali.krishna.md@gmail.com
Muralikrishna Gopal and Shaad Abdullah contributed to the study hypoth-
esis, data collection, and manuscript preparation. James Grady contrib-
uted to statistical analysis. James Goodwin contributed to study super-
vision and manuscript preparation.
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0508-1233
Journal of Thoracic Oncology • Volume 5, Number 8, August 2010 1233
hort studies and did not present the baseline findings
of RCTs.
Our objective was to perform a systematic review
and a meta-analysis of the baseline results of the five RCTs
published to date to determine whether screening for lung
cancer with LDCT in comparison with no screening or
chest radiography is effective in diagnosing lung cancers
early in a high-risk population of smokers (PICO—Pa-
tients, Interventions, Comparison, Outcomes). Because the
final results of these trials will not be available in the near
future, we attempted to determine the effectiveness of
screening by using a surrogate end point. Although lead
time bias has been used as an argument against the use of
detection of stage I cancers, it has been shown in studies
that earlier detection of lung cancers results in a survival/
mortality benefit.3 On the other hand, we also attempted to
determine whether any benefit of detecting stage I lung
cancers are offset by the harms of screening, detection of
false-positive nodules, and thoracotomies for benign le-
sions.17,22–24 Pooling the results of a relatively homoge-
neous study population across studies in a meta-analysis
provided data on 14,055 individuals.
METHODS
The PRISMA25,26 guidelines for systematic re-
views were used (see Supplemental Figure 1, Supplemen-
tal Digital Content 1, http://links.lww.com/JTO/A22). We
searched electronic databases from 1966 to February 2010
(MEDLINE, EMBASE, CINAHL, and Cochrane Library),
Radiologic Society of North America (RSNA 2003–2009),
European College of Radiology (ECR 2001–2009) meeting
abstracts, major radiology and lung cancer textbooks,
reference lists, and for completed trials not yet published.
References and related articles from studies that fit the
study population were reviewed. Articles were searched in
the above resources with the following search concepts
with their synonyms. Major search concepts included lung
neoplasm, mass screening, computed tomography, and
x-ray. These concepts were exploded to include all sub-
headings of Medical Subject Headings (MeSH) as well as
text searches for articles not yet indexed. No other search
filters were used. Non-English results were included. At-
tempt was made to find unpublished studies to avoid the
file-drawer effect by searching for abstracts as well using
our search strategy and also to include non-English studies
to decrease funnel plot asymmetry. Only data from RCTs
was used in our study. The types of participants included
those at high risk for lung cancer, age group on average
was 50 to 60 years, and the average smoking history was
20 to 30 pack-years. The intervention studied was LDCT
in a high-risk population for lung cancer versus either no
screening in three studies and chest x-ray in three others.
The types of outcome measures included detection of stage
I non-small cell lung cancer (NSCLC), all NSCLC, all lung
cancers, detection of false-positive nodules (defined as
noncalcified benign nodules more than 4 to 5 mm detected
on initial LDCT), and rate of thoracotomy for benign
lesions.
Validity assessment and assessment of risk of bias
(study level/outcome level and in/across studies) was per-
formed. All relevant articles were retrieved and indepen-
dently assessed by two reviewers (M.G. and S.E.A.), with
conflicts being resolved by a third independent review
(J.J.G.). All articles that met these criteria were then
exposed to a second stage of quality assessment. The U.S.
Preventive Services Task Force guidelines for grading the
validity of individual studies for use in systematic reviews
was applied to all potential articles,27 and the Cochrane
collaboration’s tool for assessing risk of bias28 was also
used. This was a scale that evaluated generalizability,
sample size, dropout rate, reproducibility, and statistical
methodology of each study. No studies were excluded
because of quality concerns.
The data abstraction was done by two independent
investigators (M.G. and S.E.A.) using the search criteria
above of the results of the RCTs of screening for lung
cancer using LDCT. The comprehensive meta-analysis
software version 2.2 was used for statistical analysis.29
Eight RCTs were identified comparing LDCT with no
screening or chest x-ray (CXR) in a high-risk population
for lung cancer.16,30–33 The baseline result of one RCT
(NELSON34) was not available for analysis and was ex-
cluded from further review. The results of baseline and
first repeat round have been published only for the trial
Lung Screening Study33,35; for another five RCTs to date,
we have the baseline round of results only. The enrolment
procedure was volunteer-based for all trials. The percent-
age of dropout varied in the trials: 0 to 21%. Quantitative
data synthesis was performed using the software Compre-
hensive Meta-Analysis with a random effects model ap-
proach, and the results are presented in Figures 1 through
4. Event rate and odds ratio were used as statistical end
points for each end point: stage I NSCLC, total NSCLC,
false-positive nodules, and thoracotomies for benign le-
sions. For each end point, 95% confidence intervals (CIs)
were calculated. Heterogeneity among the RCTs predom-
inantly involved the control arm, with three studies using
CXR and three using no screening. This issue was ad-
dressed by first analyzing only studies comparing CXR and
then analyzing all studies together.
RESULTS
Baseline characteristics of the study population in
each arm, including age, gender and smoking history,
length of screening, screening strategy employed (LDCT
versus none and LDCT versus CXR), collimation of
LDCT, and the year final results are expected are summa-
rized in Table 1. In total, there were 7078 individuals in
the LDCT arm and 6977 in the control arm, for a total of
14,055 individuals. Both the LDCT arm and control arm
(CXR versus no imaging) were comparable in terms of age
and smoking history. Collimation of LDCT scan varied
from 0.6 to 5 mm among trials. Work-up of nodules
detected varied between trials; fluorodeoxyglucose
positron emission tomography was not routinely included
in the nodule work-up; fine-needle aspiration was not
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always a frequent diagnostic procedure. Trials differ in
some variables, such as offering usual care or chest radio-
graph to the controls, sample size, enrolment criteria,
radiologic protocol, frequency screening regimen, CT
findings work-up, data management, and the use of a
computer-aided detection system for nodule detection and
analysis. The control arm varied between the six studies;
three studies compared LDCT with CXR whereas three
studies compared LDCT with no screening. To assess for
the effect of heterogeneity, the odds ratio for all six studies
was compared with the odds ratio for studies comparing
with CXR only for all end points. Table 2 summarizes the
end points used in the meta-analysis. This includes the
number of stage I NSCLC detected, total number of
NSCLCs detected, total number of lung cancers detected,
number of false-positive nodules detected, and number of
thoracotomies performed for benign lesions in the LDCT
arm compared with the control arm.
The forest plot for stage I NSCLCs in LDCT compared
with control arm is shown in Figure 1. The odds of detecting a
FIGURE 1. Forest plot for detec-
tion of stage I non-small cell lung
cancer (NSCLC) with low-dose com-
puted tomography (LDCT) versus
control.
TABLE 1. Baseline Characteristics of Included Studies
Name of
Study
Screening
Duration Sample Size
Trial
Randomization
Age
(yr) Sex
Smoking History (yr)/
Ex-Smokers Quit (yr)
Collimation of
LDCT Scan
(mm3)
Year Final
Results
Expected
Garg/Colorado
University16
2001 (1 yr) 92 LDCT, 98
control (190)
LDCT vs. usual care 50–80 97.4% male,
2.6%
female
30 5 n/a
ITALUNG32 2004–2006 1613 LDCT, 1593
controls (3206)
LDCT vs. usual care 55–69 64.7% male,
35.3%
female
20/10 1–3 2012
LSS33,35,45 2000–2004 1660 LDCT, 1658
CXR (3318)
LDCT vs. CXR 55–77 59% male,
41% female
30/15 (NLST), 10
(LSS)
0.6–2 (NLST)/
5 (LSS)
2011
DEPISCAN31 2002–2004 385 LDCT, 380
controls (765)
LDCT vs. CXR 50–75 71% male,
29% female
15/15 1–1.5 n/a
DANTE30 2001–2006 1276 LDCT, 1196
controls (2472)
LDCT vs. usual care 60–74 Male only 20/10 5 n/a
DANISH54 2004–2006 2052 LDCT, 2052
controls (4104)
LDCT vs. usual care 49–74 55.2% male,
44.8%
female
20 3 2011
LDCT, low-dose computed tomography; NLST, National Lung Screening Trial; LSS, Lung Screening Study.
TABLE 2. Summary of Surrogate End Points Studied in the
Meta-Analysis
Name of
Study
Screening
Method
Stage I
NSCLC
Total
Cancers
False-Positive
Nodules
Unnecessary
Thoracotomies
Garg et al.16 LDCT 1 3 27 0
None 0 0 0
ITALUNG32 LDCT 10 21 618 1
None 0 0 0
LSS33,35,45 LDCT 16 30 295 6
CXR 6 7 145
DEPISCAN31 LDCT 3 8 73 3
CXR 0 1 20
DANTE30 LDCT 16 28 171 6
CXR 4 8 29
DANISH54 LDCT 9 17 162 2
None 0 0 0
NSCLC, non-small cell lung cancer; LDCT, low-dose computed tomography; LSS,
Lung Screening Study.
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stage I NSCLC in the LDCT arm compared with control arm
was 3.9 (95% CI 2.0–7.4). The odds of detection of a NSCLC
in the LDCT arm compared with the control arm was 5.5 (95%
CI 3.1–9.6). The forest plot for this end point is shown in Figure
2. Forest plot for false-positive nodules is shown in Figure 3. An
individual in the LDCT arm was 3.1 (95% CI 2.6–3.7) times
more likely to have a false-positive nodule compared with
controls. The event rate was 3.7 per 1000 (95% CI 3.5–3.8) for
performance of thoracotomy for a benign lesion in the LDCT
arm (Figure 4). An individual was four times more likely to
undergo a thoracotomy for a benign lesion in the LDCT arm
compared with the control arm.
FIGURE 2. Forest plot for detec-
tion of total non-small cell lung can-
cer (NSCLC) with low-dose com-
puted tomography (LDCT) versus
control.
FIGURE 3. Forest plot for detec-
tion of false positive nodules with
low-dose computed tomography
(LDCT) versus control.
FIGURE 4. Forest plot for perfor-
mance of thoracotomy for benign
lesions (thoracotomy  100) in low-
dose computed tomography (LDCT)
arm versus controls.
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The effect of use of CXR in the control arm as opposed
to no screening was estimated by performing the meta-
analysis and calculating each end point for CXR studies only
and comparing the results for all six studies. None of the end
points differed significantly when compared as pooled results
of CXR in screening as opposed to no screening. This also
served as a measure of the effect of heterogeneity among the
trials. The odds ratio and the event rate with both analyses
were similar, and this is reflected in the forest plot for each
outcome, with the two results comparable, with minimal
effect of adding the studies with no screening in the control
arm. We calculated the failsafe N statistic, which estimates
the number of studies required to annul the results obtained in
a meta-analysis.36 The failsafe N statistic was calculated to be
14 for the end point of stage I NSCLC and 279 for the end
point of unnecessary thoracotomies.
DISCUSSION
A number of features make lung cancer an attractive
option for early detection and these include the presence of
a high-risk population, the relatively asymptomatic nature
of the disease in the early phase, and relatively better
prognosis when discovered early. Modalities to detect lung
cancer include chest radiography, sputum cytology, and
computed tomography. Screening with CXR and sputum
cytology has been studied in numerous observational stud-
ies and RCTs; results have not shown any reduction in
disease specific mortality, and the excess of lung cancers
in the intervention group has been attributed to overdiag-
nosis.12,37,38 Advances in computed tomography technique
have reduced the radiation exposure by the use of LDCT,
which reported to have approximately the same radiation
dose as mammography.39 The observation that CT picks up
small, asymptomatic cancers led to increased interest in
the use of CT in screening.40–42 In the 1990s, numerous
observational studies that involved a single arm of screen-
ing, including ELCAP and I-ELCAP, were published, with
CT picking up eight times more cancers than CXR.43,44
This led some to recommend immediate institution of lung
cancer screening and others to await results of RCTs.
One-arm prospective cohort studies evaluate screening in
terms of cancer detection, interval cancer cases, tumor
characteristics, and survival rates, whereas the aim of
RCTs is to compare a group of individuals offered a
screening regimen with a comparable, nonscreened, or
differently screened group to demonstrate the reduction of
mortality that would be achieved by the early diagnosis of
lung cancers. RCTs are not affected by length bias and
overdiagnosis; their results can reveal a real benefit of
screening in mortality reduction by comparing occur-
rence of the disease and mortality in the active and con-
trol group.
Worldwide, today there are nine RCTs in screening
for lung cancer ongoing or completed. The Lung Screening
Study was the first RCT to start in the year 200033; the final
analysis for lung cancer mortality is predicted for National
Lung Screening Trial in 2011,45 for ITALUNG32 in 2012,
and for NELSON46 in 2016. Our meta-analysis, to our
knowledge, is the first to be performed of the available
baseline results of the RCTs studying the effect of LDCT
in screening for lung cancer.
Benefit of screening includes the detection of early
stages of lung cancers with the possibility of surgical cure.
Only 16% of lung cancers detected during routine care are
stage I because individuals are diagnosed and worked up
when they develop symptoms from lung cancers, which often
is associated with later stages. The rate of detection of stage
I lung cancers, in comparison, is 70% with LDCT screening.
In our study, we found a significantly higher number of stage
I lung cancers, higher number of total NSCLCs, and higher
total lung cancers in the LDCT arm compared with the
control arm. In our study, we found that individuals in the
LDCT arm were 3.9 times more likely than controls to have
a stage I lung cancer detected.
The benefits of detecting more stage I NSCLC may
be offset by the harms of screening.47 Harms of screening
include overdiagnosis, detection of false-positive lesions,
and need for further work-up, which may include follow-
up, repeat imaging, biopsy, or surgery. Individuals in the
LDCT arm were 3.1 times more likely to have a false-
positive nodule detected when compared with the control
arm. In our study, we detected a rate of 4 of 1000
thoracotomies for benign lesions. This would translate to
one unnecessary thoracotomy performed for every 250
high-risk individuals screened for lung cancer with LDCT.
Limitations of our study include problems inherent to
all meta-analyses48 and heterogeneity among included stud-
ies, especially with CXR being used for screening in the
control arm in three studies and no screening in the other
three studies. Baseline results of one RCT (NELSON) were
also not available for our analysis. Studies varied in protocol
by which LDCT was obtained, methodology of follow-up,
and work-up of noncalcified nodules detected. Other sur-
rogate end points of harm, which were not analyzed in our
study, are the number of unnecessary bronchoscopies per-
formed and the number of transbronchial/transthoracic
biopsies performed on benign lesions.
A number of unanswered questions remain with
regard to screening for lung cancer with LDCT. The
optimal frequency, length, and collimation of LDCT
screening and the protocol for follow-up of noncalcified
nodules are not known. In current smokers, primary pre-
vention of lung cancer with smoking cessation should go
hand in hand with screening for early-stage lung cancer if
screening is implemented. positron emission tomography
scanning has not been studied as a modality to screen for
lung cancers but showed a sensitivity of 50% for detection
of all cancers in one study.49
There are numerous limitations with lung cancer
screening. One significant qualitative factor that is not
studied in clinical trials is the psychologic impact of
screening50,51; anxiety and mental issues can arise in indi-
viduals and their families who have suspicious lesions on
initial screening who have to undergo repeat screening,
especially with the high rate of false-positive nodules
detected, as demonstrated in our meta-analysis. Occur-
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rence of interval cancers and the performance of unneces-
sary procedures (biopsy/thoracotomy) are potential limita-
tions with lung cancer screening. Some lung cancers
detected by screening may never progress to cause symp-
toms or death in that individual’s lifetime and therefore
may be overdiagnosed by screening.52 Finally, cost effec-
tiveness will be an important determinant of the incorpo-
ration of screening strategies into national guidelines.53
The cumulative adverse end points of additional false
positives, follow-up of those false positives, unnecessary
procedures, cost, and psychologic burden point toward the
possible superiority of baseline results over follow-up
imaging.
LDCT seems to be better than CXR in detecting lung
cancer, as shown in other studies and in our meta-analysis.
Screening for lung cancer using LDCT resulted in detec-
tion of significantly more stage I lung cancers, more total
NSCLCs, and more total lung cancers. Screening using
LDCT also resulted in detection of more false-positive
nodules and more unnecessary thoracotomies for benign
lesions. For every 1000 individuals screened with LDCT
for lung cancer, 9 stage I NSCLC and 235 false-positive
nodules would be detected, and four thoracotomies for
benign lesions would be performed. The systematic review
and meta-analysis of the baseline data from six RCTs offer
no compelling evidence either in favor or against LDCT
screening for lung cancer. We await the final results of
these RCTs to improve our understanding of the effective-
ness of LDCT in the screening for lung cancer and its
effect on mortality.
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